5 major pharmas set for mixed Q2 results as new drugs and global expansion hold key
Second-quarter earnings for South Korea's top five pharmaceutical companies are expected to diverge by firm. While revenue grew for most, operating profit is analyzed to show differences depending on the products that drove growth. Companies that led growth centered on new drugs and overseas operations are expected to see relatively solid profitability, with..